Browse News
Filter News
Found 135 articles
-
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
4/2/2024
Vaccinex, Inc. today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
-
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
3/27/2024
Vaccinex, Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant.
-
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
2/21/2024
Vaccinex, Inc. (Nasdaq: VCNX) announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.
-
Vaccinex, Inc. Announces Reverse Stock Split - February 15, 2024
2/15/2024
Vaccinex, Inc. announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024.
-
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
2/7/2024
Vaccinex, Inc. announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company’s Board of Directors and the Company’s Chief Executive Officer.
-
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
12/4/2023
Vaccinex, Inc. previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in compliance with Nasdaq’s minimum bid price requirement and that Nasdaq could move to suspend trading of the common stock and to delist the Company’s securities unless the company appealed Nasdaq’s determination.
-
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
Vaccinex, Inc. today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.
-
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
10/31/2023
Vaccinex, Inc. will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, CA November 1-5, 2023.
-
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
10/26/2023
Vaccinex, Inc., a clinical-stage biotechnology company, reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease Conference in Boston, MA.
-
Vaccinex Announces Pricing of $9.6 Million Public Offering
9/29/2023
The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
-
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
9/28/2023
Vaccinex, Inc. announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery.
-
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
9/27/2023
Vaccinex, Inc today announced that it will present data on a new ActivMAb® application on September 28th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29th.
-
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
9/26/2023
Vaccinex, Inc., a clinical-stage biotechnology company will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer’s and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences.
-
Vaccinex, Inc. Announces Reverse Stock Split
9/22/2023
Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that it will effect a 1-for-15 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, September 25, 2023.
-
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/14/2023
Vaccinex, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
-
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
6/1/2023
Vaccinex, Inc. announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 to 10:25 am Eastern Time in New York City, NY and invites investors to participate in one-on-one meetings that same day.
-
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/15/2023
Vaccinex, Inc. (Nasdaq: VCNX) today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update on key programs and financing in the first five months of the year.
-
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
4/25/2023
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer’s Disease (NCT04381468).
-
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
4/12/2023
Vaccinex, Inc. today announced a new publication in the March 30, 2022 issue of Nature Communications describing a novel way that the ActivMAb® platform can be used for functional studies and drug discovery of the “hard to drug” class of membrane-associated G protein-coupled receptors (GPCRs) and ion channels.
-
Vaccinex Announces Private Placement with Commitments of $5.0 Million
4/3/2023
Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that on March 30, 2023 the company closed the private placement of an aggregate of 4,975,608 shares of its common stock at a purchase price of $0.41 per share for aggregate gross proceeds of $2.04 million.